Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
- Conditions
- HIV Infections
- Interventions
- Drug: Oral CABDrug: Oral TDF/FTCDrug: Placebo for oral CABDrug: Placebo for CAB LADrug: Placebo for oral TDF/FTC
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-09-30
- Target Recruit Count
- 3224
- Registration Number
- NCT03164564
- Locations
- 🇿🇼
St Mary's CRS, Chitungwiza, Zimbabwe
🇧🇼Gaborone CRS, Gaborone, South-East District, Botswana
🇺🇬MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
Targeted Microbiome Transplant in Atopic Dermatitis
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- Biological: TMT LotionDrug: Placebo Lotion
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-08-17
- Target Recruit Count
- 54
- Registration Number
- NCT03151148
- Locations
- 🇺🇸
University of California - San Diego, San Diego, California, United States
🇺🇸National Jewish Health General Clinical Research Center, Denver, Colorado, United States
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
- Conditions
- TuberculosisHIV Infections
- Interventions
- Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2025-01-17
- Target Recruit Count
- 37
- Registration Number
- NCT03141060
- Locations
- 🇮🇳
Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
🇿🇦Sizwe CRS, Johannesburg, Gauteng, South Africa
🇿🇦PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
- Conditions
- HIV Infections
- Interventions
- Biological: ALVAC-HIV (vCP2438)Biological: Bivalent subtype C gp120/MF59Biological: Bivalent subtype C gp120/AS01(B)Biological: Placebo
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2023-03-14
- Target Recruit Count
- 160
- Registration Number
- NCT03122223
- Locations
- 🇺🇸
Fenway Health (FH) CRS, Boston, Massachusetts, United States
🇺🇸Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
🇺🇸Bridge HIV CRS, San Francisco, California, United States
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2025-04-27
- Target Recruit Count
- 250
- Registration Number
- NCT03109288
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
- Conditions
- Schistosomiasis
- Interventions
- Biological: Sm-TSP-2/AlhydrogelBiological: GLA-AFBiological: Hepatitis B Virus Vaccine (Recombinant)
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2021-02-02
- Target Recruit Count
- 60
- Registration Number
- NCT03110757
- Locations
- 🇧🇷
Americaninhas Vaccine Center, Novo Oriente, Minas Gerais, Brazil
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
- Conditions
- Zika Virus InfectionFlaviviral DiseasesVirus DiseasesRNA Virus InfectionsZika VirusFlavivirus InfectionsFlaviviridae Infections
- Interventions
- Biological: VRC-ZKADNA090-00-VPOther: VRC-PBSPLA043-00-VP
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2024-01-31
- Target Recruit Count
- 2428
- Registration Number
- NCT03110770
- Locations
- 🇵🇦
Instituto Conmemorativo Gorgas, Panamá, San Miguelito Province, Panama
🇵🇷Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico
🇨🇴Clinica de la Costa Ltda, Barranquilla, Atlantico, Colombia
Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: D46/NS2/N/ΔM2-2-HindIIIBiological: Placebo
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-02-08
- Target Recruit Count
- 32
- Registration Number
- NCT03102034
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
🇺🇸David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
- Conditions
- Ebola Virus Disease
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-08-22
- Target Recruit Count
- 4830
- Registration Number
- NCT03098862
- Locations
- 🇱🇷
PREVAIL C. H. Rennie Hospital, Kalkata, Liberia
🇱🇷PREVAIL JFK Medical Center, Monrovia, Liberia
🇱🇷PREVAIL Duport Road Clinic, Paynesville, Liberia
Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)
- Conditions
- Herpes Virus-Related Illnesses
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2025-04-11
- Target Recruit Count
- 190
- Registration Number
- NCT03092505
- Locations
- 🇺🇬
Rakai, Kalisizo, and Villa Maria Hospital, Kalisizo, Uganda
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States